Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Argent Biopharma ( (AU:RGT) ).
Argent Biopharma Limited announced the cessation of certain securities, specifically the lapse of 306,000 performance rights and the expiry of 250 Class D performance rights as of April 30, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s performance and future prospects.
More about Argent Biopharma
Argent Biopharma Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is listed on the Australian Securities Exchange (ASX) under the issuer code RGT.
YTD Price Performance: -25.00%
Average Trading Volume: 1,165
Technical Sentiment Signal: Buy
Current Market Cap: $5.15M
See more data about RGT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue